RxDoctor Payments Data

Karel Calero, MD

Pulmonary Disease · Tampa, FLNPI 1194979245

Payments from drug & device makers

What this record shows

The money is spread across several categories — education (48.6%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 79.9% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2022 at $4,073 and has fallen 77.3% since, to $924 in 2025.

$6,177in general payments, 2019–2025

Across 26 payments — averaging $237.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$5K
  • Inspire Medical Systems, Inc.$693
  • Boehringer Ingelheim$244
  • ZOLL Respicardia, Inc.$187
  • Philips North America LLC$74
  • Baxter Healthcare$24
  • plus $20 from 1 others
$536,268in research payments, 2019–2025

Across 74 payments — averaging $7246.87 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Incyte Corporation$342K
  • Spiration, Inc.$140K
  • Baxter Healthcare$50K
  • Gyrus ACMI, Inc.$4K

What the payments were for

  • Travel & lodging$1,76929%
  • Food & beverage$1,40723%
  • Education$3,00049%

General payments by program year

19
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,177 in reported general payments places this provider in the 60th percentile of 953 pulmonary disease providers in Florida.

See all pulmonary disease providers in Florida

Medicare billing

Part B allowed, 2024
$29,035
Medicare patients
164
Services billed
257

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate11$143,811
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$19,454
Incruse ElliptaUmeclidinium Bromide12$4,723
Albuterol Sulfate HfaAlbuterol Sulfate14$496
Azithromycin11$37

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev$244$143,81111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 953 pulmonary disease providers in Florida.

Other pulmonary disease in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →